Oscar K Serrano1, Patricia Friedmann2, Sayeeda Ahsanuddin3, Carlos Millan1, Almog Ben-Yaacov4, Liise K Kayler5. 1. Department of Surgery, Montefiore Medical Center, Bronx, New York; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York; 2. Department of Medicine, Albert Einstein College of Medicine, Bronx, New York; 3. Department of Surgery, Case Western Reserve, Cleveland, Ohio; and. 4. Department of Surgery, Rabin Medical Center, Petah Tikva, Israel. 5. Department of Surgery, Montefiore Medical Center, Bronx, New York; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York; liisekayler@yahoo.com.
Abstract
BACKGROUND AND OBJECTIVES: Alemtuzumab is a humanized anti-CD52 monoclonal antibody used as induction in kidney transplantation (KTX) since 2003. Few studies have evaluated long-term outcomes of this agent or changes in outcomes over time. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A retrospective cohort study was performed examining United States registry data from 2003 to 2014 of primary KTX recipients receiving induction with alemtuzumab (AZ; n=5521) or antithymocyte globulin (ATG; n=8504) and maintenance immunosuppression with tacrolimus and mycophenolate mofetil and early withdrawal of steroids. The primary outcome was overall death-censored graft survival (DCGS), and secondary outcomes were overall patient survival and 1-year acute rejection. Multivariate models were fit with donor, recipient, and transplant covariates. Because poorer outcomes with AZ may occur from a learning curve impact with the use of a new medication, transplant year was categorized into three time periods to evaluate outcomes over time (2003-2005, 2006-2008, ≥2009), and an interaction term of induction type with transplant year category was included in all models to test for era impacts. RESULTS: On multivariate analysis of DCGS there was a significant interaction between AZ and era (P<0.001). AZ was significantly associated with inferior DCGS in the earliest 2003-2005 era (adjusted hazard ratio [aHR], 2.21; 95% confidence interval [95% CI], 1.72 to 2.84) but not in the middle 2006-2008 era (aHR, 1.14; 95% CI, 0.96 to 1.36) or the most recent 2009-2014 era (aHR, 1.08; 95% CI, 0.90 to 1.29) compared with ATG. Risk-adjusted patient survival (aHR, 1.32; 95% CI, 1.08 to 1.61; aHR, 1.26; 95% CI, 1.09 to 1.46; and aHR, 1.10; 95% CI, 0.93 to 1.29 by era, respectively) and acute rejection (adjusted odds ratio [aOR], 1.17; 95% CI, 0.96 to 1.42; aOR, 0.94; 95% CI, 0.82 to 1.07; aOR, 0.89; 95% CI, 0.81 to 0.98 by era, respectively) with AZ was comparable with ATG in the most recent era; however, there was no significant interaction with time (P=0.13 and P=0.06, respectively). CONCLUSIONS: Current alemtuzumab utilization is associated with comparable graft and patient survival and acute rejection compared with ATG. Graft survival with alemtuzumab has improved over time.
BACKGROUND AND OBJECTIVES:Alemtuzumab is a humanized anti-CD52 monoclonal antibody used as induction in kidney transplantation (KTX) since 2003. Few studies have evaluated long-term outcomes of this agent or changes in outcomes over time. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A retrospective cohort study was performed examining United States registry data from 2003 to 2014 of primary KTX recipients receiving induction with alemtuzumab (AZ; n=5521) or antithymocyte globulin (ATG; n=8504) and maintenance immunosuppression with tacrolimus and mycophenolate mofetil and early withdrawal of steroids. The primary outcome was overall death-censored graft survival (DCGS), and secondary outcomes were overall patient survival and 1-year acute rejection. Multivariate models were fit with donor, recipient, and transplant covariates. Because poorer outcomes with AZ may occur from a learning curve impact with the use of a new medication, transplant year was categorized into three time periods to evaluate outcomes over time (2003-2005, 2006-2008, ≥2009), and an interaction term of induction type with transplant year category was included in all models to test for era impacts. RESULTS: On multivariate analysis of DCGS there was a significant interaction between AZ and era (P<0.001). AZ was significantly associated with inferior DCGS in the earliest 2003-2005 era (adjusted hazard ratio [aHR], 2.21; 95% confidence interval [95% CI], 1.72 to 2.84) but not in the middle 2006-2008 era (aHR, 1.14; 95% CI, 0.96 to 1.36) or the most recent 2009-2014 era (aHR, 1.08; 95% CI, 0.90 to 1.29) compared with ATG. Risk-adjusted patient survival (aHR, 1.32; 95% CI, 1.08 to 1.61; aHR, 1.26; 95% CI, 1.09 to 1.46; and aHR, 1.10; 95% CI, 0.93 to 1.29 by era, respectively) and acute rejection (adjusted odds ratio [aOR], 1.17; 95% CI, 0.96 to 1.42; aOR, 0.94; 95% CI, 0.82 to 1.07; aOR, 0.89; 95% CI, 0.81 to 0.98 by era, respectively) with AZ was comparable with ATG in the most recent era; however, there was no significant interaction with time (P=0.13 and P=0.06, respectively). CONCLUSIONS: Current alemtuzumab utilization is associated with comparable graft and patient survival and acute rejection compared with ATG. Graft survival with alemtuzumab has improved over time.
Authors: Matthew P Welberry Smith; Aravind Cherukuri; Chas G Newstead; Andrew J P Lewington; Niaz Ahmad; Krish Menon; Stephen G Pollard; Padmini Prasad; Steve Tibble; Emma Giddings; Richard J Baker Journal: Transplantation Date: 2013-12-27 Impact factor: 4.939
Authors: Raymond L Heilman; Hasan A Khamash; Maxwell L Smith; Harini A Chakkera; Adyr A Moss; Kunam S Reddy Journal: Clin Transplant Date: 2013-08-08 Impact factor: 2.863
Authors: Michael J Hanaway; E Steve Woodle; Shamkant Mulgaonkar; V Ram Peddi; Dixon B Kaufman; M Roy First; Richard Croy; John Holman Journal: N Engl J Med Date: 2011-05-19 Impact factor: 91.245
Authors: A Cherukuri; A D Salama; C Carter; N Smalle; R McCurtin; E W Hewitt; M Hernandez-Fuentes; B Clark; R J Baker Journal: Am J Transplant Date: 2012-03-05 Impact factor: 8.086
Authors: Kakit Chan; David Taube; Candice Roufosse; Terence Cook; Paul Brookes; Dawn Goodall; Jack Galliford; Tom Cairns; Anthony Dorling; Neill Duncan; Nadey Hakim; Andrew Palmer; Vassilios Papalois; Anthony N Warrens; Michelle Willicombe; Adam G McLean Journal: Transplantation Date: 2011-10-15 Impact factor: 4.939
Authors: Neel Koyawala; Jeffrey H Silber; Paul R Rosenbaum; Wei Wang; Alexander S Hill; Joseph G Reiter; Bijan A Niknam; Orit Even-Shoshan; Roy D Bloom; Deirdre Sawinski; Susanna Nazarian; Jennifer Trofe-Clark; Mary Ann Lim; Jesse D Schold; Peter P Reese Journal: J Am Soc Nephrol Date: 2017-03-20 Impact factor: 10.121
Authors: Vikas R Dharnidharka; Abhijit S Naik; David A Axelrod; Mark A Schnitzler; Zidong Zhang; Sunjae Bae; Dorry L Segev; Daniel C Brennan; Tarek Alhamad; Rosemary Ouseph; Ngan N Lam; Mustafa Nazzal; Henry Randall; Bertram L Kasiske; Mara McAdams-Demarco; Krista L Lentine Journal: Transpl Int Date: 2017-11-02 Impact factor: 3.782